Dermata Therapeutics (DRMA)
NASDAQ:DRMA
Top Page
Dermata Therapeutics
(NASDAQ:DRMA)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.50
▼(-29.91% Downside)
Action:ReiteratedDate:03/27/26
The score is driven primarily by weak financial performance (no revenue, deepening losses, and heavy cash burn). Technicals add downside bias with the stock below key longer-term moving averages and a negative MACD. A recent financing provides some near-term funding support, but valuation metrics given offer little help.
Positive Factors
Strengthening IP
Patent acceptance in Australia strengthens Dermata's intellectual property around its BDS dermal filler program, reinforcing a legal moat for product exclusivity. Durable IP protection supports licensing, partner deals, and long-term commercialization optionality across geographies.
Negative Factors
No Revenue Base
Absence of a revenue stream means Dermata lacks validated commercial products and must fund operations via financing. This structural gap increases execution risk: clinical success and regulatory approvals must precede durable cash generation, extending dependency on external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Strengthening IP
Patent acceptance in Australia strengthens Dermata's intellectual property around its BDS dermal filler program, reinforcing a legal moat for product exclusivity. Durable IP protection supports licensing, partner deals, and long-term commercialization optionality across geographies.
Read all positive factors
Dermata Therapeutics (DRMA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.91M
Dividend YieldN/A
Average Volume (3M)249.42K
Price to Earnings (P/E)―
Beta (1Y)1.10
Revenue GrowthN/A
EPS Growth90.53%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.35
Shares Outstanding4,022,143
10 Day Avg. Volume611,626
30 Day Avg. Volume249,418
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-1.36
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.88
Forecast
1Y Price Target
$4.00Price Target Upside86.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.01
Revenue Forecast (FY)$15.00M
Dermata Therapeutics Business Overview & Revenue Model
Company Description
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product ca...
How the Company Makes Money
null...
Dermata Therapeutics Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
34
Negative
Cash Flow
12
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -7.77M | -12.29M | 247.22K | -9.61M | -7.86M |
| Net Income | -7.56M | -12.29M | -7.79M | -9.61M | -7.90M |
Balance Sheet | |||||
| Total Assets | 7.86B | 3.53M | 7.98M | 6.94M | 11.62M |
| Cash, Cash Equivalents and Short-Term Investments | 7.52B | 3.16M | 7.44M | 6.24M | 10.80M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.64B | 1.97M | 1.62M | 922.63K | 1.52M |
| Stockholders Equity | 6.22B | 1.56M | 6.36M | 6.02M | 10.11M |
Cash Flow | |||||
| Free Cash Flow | -7.76B | -11.16M | -6.41M | -8.83M | -5.69M |
| Operating Cash Flow | -7.76B | -11.16M | -6.41M | -8.83M | -5.69M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 12.12B | 6.89M | 7.61M | 4.28M | 15.96M |
Dermata Therapeutics Technical Analysis
Negative
2.14
Price Trends
1.42
Negative
1.94
Negative
3.67
Negative
Market Momentum
-0.05
Negative
44.52
Neutral
41.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DRMA, the sentiment is Negative. The current price of 2.14 is above the 20-day moving average (MA) of 1.29, above the 50-day MA of 1.42, and below the 200-day MA of 3.67, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 44.52 is Neutral, neither overbought nor oversold. The STOCH value of 41.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DRMA.
Dermata Therapeutics Risk Analysis
Dermata Therapeutics disclosed 86 risk factors in its most recent earnings report. Dermata Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Dermata Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
DRMA
Dermata Therapeutics
1.22
-6.87
-84.92%
REVB
Revelation Biosciences
1.17
-40.59
-97.20%
CERO
CERo Therapeutics Holdings
0.03
-13.39
-99.78%
PBM
Psyence Biomedical
2.67
-20.84
-88.64%
AZTR
Azitra Inc
0.23
-1.72
-88.32%
Dermata Therapeutics Corporate Events
Executive/Board Changes
Dermata Therapeutics Announces Board Resignation and Size Reduction
Neutral
Feb 25, 2026
On February 23, 2026, Dermata Therapeutics, Inc. announced that board member Mary Fisher has submitted her resignation from the company’s Board of Directors, effective March 31, 2026. The company stated that her departure was not due to any ...
Private Placements and Financing
Dermata Therapeutics Expands At-The-Market Equity Offering Capacity
Neutral
Jan 27, 2026
On January 27, 2026, Dermata Therapeutics, Inc. increased the maximum aggregate amount of common stock it may issue under its at-the-market offering program with H.C. Wainwright Co., LLC by an additional $705,000, following prior sales of $3,454,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.